Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag EstimatesZacks Investment Research • Thursday
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory InfectionsBusiness Wire • 10/21/26
Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 10/14/26
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.Business Wire • 10/05/26
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026Business Wire • 09/09/26
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial ThreatsBusiness Wire • 08/28/26
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings EstimatesZacks Investment Research • 08/03/26
Shionogi Recognizes the Four-Year Anniversary of RADICAVA ORS® (edaravone) for Treatment of ALSBusiness Wire • 07/30/26
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 07/20/26
FDA Accepts Shionogi's sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative BacteriaBusiness Wire • 07/16/26
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following ExposureBusiness Wire • 06/01/26
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following ExposureBusiness Wire • 05/13/26
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial ThreatsBusiness Wire • 04/08/26
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe DiseaseBusiness Wire • 03/19/26
All You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to BuyZacks Investment Research • 02/03/26